2-chloroadenosine has been researched along with nicardipine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Asano, S; Bender, SB; Borbouse, L; Bratz, IN; Dick, GM; Dincer, UD; Neeb, ZP; Payne, GA; Sturek, M; Tune, JD | 1 |
1 other study(ies) available for 2-chloroadenosine and nicardipine
Article | Year |
---|---|
Impaired function of coronary BK(Ca) channels in metabolic syndrome.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 2-Chloroadenosine; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Arterioles; Benzimidazoles; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Signaling; Coronary Circulation; Coronary Vessels; Diet, Atherogenic; Disease Models, Animal; Dose-Response Relationship, Drug; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Large-Conductance Calcium-Activated Potassium Channel beta Subunits; Large-Conductance Calcium-Activated Potassium Channels; Male; Membrane Potentials; Metabolic Syndrome; Microcirculation; Muscle, Smooth, Vascular; Mycotoxins; Nicardipine; Peptides; Phenotype; Potassium Channel Blockers; Swine; Swine, Miniature; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2009 |